Summary

Asia-Pacific blood plasma & plasma derived medicinal products market is expected to reach USD 11.61 billion by 2032 from USD 5.96 billion in 2024, growing at a CAGR of 8.73% during the forecast period of 2025 to 2032.

Market Segmentation:
Asia-Pacific Blood Plasma & Plasma Derived Medicinal Products Market, By Product (Immunoglobulins, Coagulation Factors (For Bleeding Disorders), Albumin (Plasma Volume Expander), Protease Inhibitors (For Genetic Deficiencies), Monoclonal Antibodies (Derived From Plasma Cells), and Other Plasma Derived Proteins), Application (Immunology, Hematology, Critical Care, Neurology, Pulmonology, Haemato-Oncology, Rheumatology, and Other Applications), Processing Technology (Ion Exchange Chromatography, Affinity Chromatography, Cryoprecipitation, Ultrafiltration, and Microfiltration), Mode (Modern and Traditional Plasma Fractionation), End-User (Hospitals & Clinics, Research Labs, Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (China, Japan, South Korea, Australia, India, Malaysia, Thailand, Singapore, Philippines, Indonesia, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2032
Overview of the Asia-Pacific Blood Plasma & Plasma Derived Medicinal Market Dynamics:

Drivers
• Rising prevalence of rare and chronic diseases
• Expanding geriatric population
Restraints
• High cost and complex manufacturing process
• Lack of plasma supply and donor
Opportunities
• Advancements in plasma processing technologies to enhance yield and reduce costs
• Reimbursement frameworks and increased governmental focus on rare disease treatment
Market Players:
The key players operating in the Asia-Pacific blood plasma & plasma derived medicinal products market are:
• CSL
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Octapharma AG
• Kedrion
• Aegros
• Bharat Serums
• Biotest AG
• Fresenius Kabi AG
• GC Biopharma corporate
• ICHOR
• Intas Pharmaceuticals Ltd.
• Kamada Pharmaceuticals
• KM Biologics
• PlasmaGen BioSciences Pvt. Ltd.
• Proliant Health & Biologicals
• Promea
• Reliance Life Sciences
• Sichuan Yuanda Shyuang Pharmaceutical Co., Ltd.
• SK Plasma
• Synthaverse S. A.
• Taibang Bio Group Co., Ltd
• VIRCHOW BIOTECH

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 89
1.1 OBJECTIVES OF THE STUDY 89
1.2 MARKET DEFINITION 89
1.3 OVERVIEW OF THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 89
1.4 LIMITATIONS 91
1.5 MARKETS COVERED 92
2 MARKET SEGMENTATION 95
2.1 MARKETS COVERED 95
2.2 GEOGRAPHICAL SCOPE 96
2.3 YEARS CONSIDERED FOR THE STUDY 97
2.4 CURRENCY AND PRICING 97
2.5 DBMR TRIPOD DATA VALIDATION MODEL 98
2.6 MULTIVARIATE MODELLING 101
2.7 PRODUCT LIFELINE CURVE 101
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 102
2.9 DBMR MARKET POSITION GRID 103
2.10 MARKET END USER COVERAGE GRID 104
2.11 VENDOR SHARE ANALYSIS 105
2.12 SECONDARY SOURCES 106
2.13 ASSUMPTIONS 106
3 EXECUTIVE SUMMARY 107
4 PREMIUM INSIGHTS 112
4.1 PESTLE ANALYSIS 113
4.1.1 POLITICAL FACTORS 113
4.1.2 ECONOMIC FACTORS 113
4.1.3 SOCIAL FACTORS 113
4.1.4 TECHNOLOGICAL FACTORS 114
4.1.5 ENVIRONMENTAL FACTORS 114
4.1.6 LEGAL FACTORS 114
4.2 PORTER’S FIVE FORCES 115
4.2.1 THREAT OF NEW ENTRANTS 115
4.2.2 BARGAINING POWER OF SUPPLIERS 115
4.2.3 BARGAINING POWER OF BUYERS 116
4.2.4 THREAT OF SUBSTITUTES 116
4.2.5 INDUSTRY RIVALRY 116
4.3 SUPPLY CHAIN IMPACT ON THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 117
4.3.1 OVERVIEW 117
4.3.2 RAW MATERIAL AVAILABILITY 117
4.3.3 MANUFACTURING CAPACITY 117
4.3.4 LOGISTICS AND LAST-MILE HURDLES 117
4.3.5 PRICING MODELS AND MARKET POSITIONING 118
4.4 INNOVATION STRATEGIES 119
4.4.1 KEY INNOVATION STRATEGIES 119
4.4.2 EMERGING DELIVERY TECHNIQUES 120
4.4.3 STRATEGIC IMPLICATIONS 120
4.4.4 CONCLUSION 120
4.5 RISK AND MITIGATION 121
4.6 VENDOR SELECTION DYNAMICS 123
4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE 123
4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY 123
4.6.3 CLINICAL EFFICACY AND INNOVATION 123
4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY 123
4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE 123
4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY 124
4.6.7 CONCLUSION 124
4.7 TARIFFS AND THEIR IMPACT ON MARKET 125
4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS 125
4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE 125
4.7.3 VENDOR SELECTION CRITERIA DYNAMICS 125
4.7.4 IMPACT ON SUPPLY CHAIN 126
4.7.5 IMPACT ON PRICES 126
4.7.6 REGULATORY INCLINATION 126
4.7.6.1 GCC TRADE ALIGNMENT & FTAS 126
4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS 126
4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE 126
4.7.6.4 DOMESTIC COURSE OF CORRECTION 126
5 REGULATION COVERAGE 128
6 MARKET OVERVIEW 131
6.1 DRIVERS 133
6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES 133
6.1.2 EXPANDING GERIATRIC POPULATION 133
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION 134
6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT 135
6.2 RESTRAINTS 136
6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS 136
6.2.2 LACK OF PLASMA SUPPLY AND DONOR 136
6.3 OPPORTUNITIES 137
6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS 137
6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT 138
6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN ASIA-PACIFIC MARKET PENETRATION 139
6.4 CHALLENGES 140
6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES 140
6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION 140
7 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT 142
7.1 OVERVIEW 143
7.2 IMMUNOGLOBULINS 146
7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS) 148
7.4 ALBUMIN (PLASMA VOLUME EXPANDER) 153
7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) 154
7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) 156
7.7 OTHER PLASMA DERIVED PROTEINS 157
8 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION 159
8.1 OVERVIEW 160
8.2 IMMUNOLOGY 163
8.3 HEMATOLOGY 163
8.4 CRITICAL CARE 164
8.5 NEUROLOGY 164
8.6 PULMONOLOGY 165
8.7 HAEMATO-ONCOLOGY 165
8.8 RHEUMATOLOGY 166
8.9 OTHER APPLICATIONS 166
9 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY 167
9.1 OVERVIEW 168
9.2 ION EXCHANGE CHROMATOGRAPHY 171
9.3 AFFINITY CHROMATOGRAPHY 171
9.4 CRYOPRECIPITATION 172
9.5 ULTRAFILTRATION 172
9.6 MICROFILTRATION 173
10 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE 174
10.1 OVERVIEW 175
10.2 MODERN 178
10.3 TRADITIONAL PLASMA FRACTIONATION 178
11 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER 179
11.1 OVERVIEW 180
11.2 HOSPITALS & CLINICS 183
11.3 RESEARCH LABS 183
11.4 ACADEMIC INSTITUTES 184
11.5 OTHERS 184
12 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 185
12.1 OVERVIEW 186
12.2 DIRECT TENDERS 189
12.3 THIRD PARTY DISTRIBUTORS 189
12.4 OTHERS 190
13 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION 191
13.1 ASIA-PACIFIC 192
13.1.1 CHINA 203
13.1.2 JAPAN 212
13.1.3 SOUTH KOREA 221
13.1.4 AUSTRALIA 230
13.1.5 INDIA 239
13.1.6 MALAYSIA 248
13.1.7 THAILAND 257
13.1.8 SINGAPORE 266
13.1.9 PHILIPPINES 275
13.1.10 INDONESIA 284
13.1.11 NEW ZEALAND 293
13.1.12 VIETNAM 302
13.1.13 TAIWAN 310
13.1.14 REST OF ASIA-PACIFIC 318
14 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE 319
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 319
15 SWOT ANALYSIS 320
16 COMPANY PROFILE 321
16.1 CSL 321
16.1.1 COMPANY SNAPSHOT 321
16.1.2 REVENUE ANALYSIS 321
16.1.3 COMPANY SHARE ANALYSIS 322
16.1.4 PRODUCT PORTFOLIO 322
16.1.5 RECENT DEVELOPMENTS 323
16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 324
16.2.1 COMPANY SNAPSHOT 324
16.2.2 REVENUE ANALYSIS 325
16.2.3 COMPANY SHARE ANALYSIS 325
16.2.4 PRODUCT PORTFOLIO 326
16.2.5 RECENT DEVELOPMENTS 326
16.3 GRIFOLS, S.A. 327
16.3.1 COMPANY SNAPSHOT 327
16.3.2 REVENUE ANALYSIS 327
16.3.3 COMPANY SHARE ANALYSIS 328
16.3.4 PRODUCT PORTFOLIO 328
16.3.5 RECENT DEVELOPMENTS 330
16.4 OCTAPHARMA AG 331
16.4.1 COMPANY SNAPSHOT 331
16.4.2 COMPANY SHARE ANALYSIS 331
16.4.3 PRODUCT PORTFOLIO 332
16.4.4 RECENT DEVELOPMENTS 334
16.5 KEDRION 335
16.5.1 COMPANY SNAPSHOT 335
16.5.2 COMPANY SHARE ANALYSIS 335
16.5.3 PRODUCT PORTFOLIO 336
16.5.4 RECENT DEVELOPMENT 336
16.6 ADMA BIOLOGICS, INC 337
16.6.1 COMPANY SNAPSHOT 337
16.6.2 REVENUE ANALYSIS 337
16.6.3 PRODUCT PORTFOLIO 338
16.6.4 RECENT DEVELOPMENT 338
16.7 AEGROS 339
16.7.1 COMPANY SNAPSHOT 339
16.7.2 PRODUCT PORTFOLIO 339
16.7.3 RECENT DEVELOPMENT 339
16.8 BHARAT SERUMS 340
16.8.1 COMPANY SNAPSHOT 340
16.8.2 PRODUCT PORTFOLIO 340
16.8.3 RECENT DEVELOPMENT 340
16.9 BIOTEST AG. 341
16.9.1 COMPANY SNAPSHOT 341
16.9.2 REVENUE ANALYSIS 341
16.9.3 PRODUCT PORTFOLIO 342
16.9.4 RECENT DEVELOPMENTS 344
16.10 FRESENIUS KABI AG 345
16.10.1 COMPANY SNAPSHOT 345
16.10.2 PRODUCT PORTFOLIO 345
16.10.3 RECENT DEVELOPMENT 345
16.11 GC BIOPHARMA CORPORATE 346
16.11.1 COMPANY SNAPSHOT 346
16.11.2 REVENUE ANALYSIS 346
16.11.3 PRODUCT PORTFOLIO 347
16.11.4 RECENT DEVELOPMENT 348
16.12 ICHOR 349
16.12.1 COMPANY SNAPSHOT 349
16.12.2 PRODUCT PORTFOLIO 349
16.12.3 RECENT DEVELOPMENT 353
16.13 INTAS PHARMACEUTICALS LTD. 354
16.13.1 COMPANY SNAPSHOT 354
16.13.2 PRODUCT PORTFOLIO 354
16.13.3 RECENT DEVELOPMENT 354
16.14 KAMADA PHARMACEUTICALS 355
16.14.1 COMPANY SNAPSHOT 355
16.14.2 REVENUE ANALYSIS 355
16.14.3 PRODUCT PORTFOLIO 356
16.14.4 RECENT DEVELOPMENT 357
16.15 KM BIOLOGICS 358
16.15.1 COMPANY SNAPSHOT 358
16.15.2 PRODUCT PORTFOLIO 358
16.15.3 RECENT DEVELOPMENT 358
16.16 LFB 359
16.16.1 COMPANY SNAPSHOT 359
16.16.2 PRODUCT PORTFOLIO 359
16.16.3 RECENT DEVELOPMENT 361
16.17 PLASMAGEN BIOSCIENCES PVT. LTD. 362
16.17.1 COMPANY SNAPSHOT 362
16.17.2 PRODUCT PORTFOLIO 362
16.17.3 RECENT DEVELOPMENTS 364
16.18 PROLIANT HEALTH & BIOLOGICALS 365
16.18.1 COMPANY SNAPSHOT 365
16.18.2 PRODUCT PORTFOLIO 365
16.18.3 RECENT DEVELOPMENT 365
16.19 PROMEA 366
16.19.1 COMPANY SNAPSHOT 366
16.19.2 PRODUCT PORTFOLIO 366
16.19.3 RECENT DEVELOPMENT 367
16.20 RELIANCE LIFE SCIENCES 368
16.20.1 COMPANY SNAPSHOT 368
16.20.2 BUSINESS PORTFOLIO 368
16.20.3 RECENT DEVELOPMENT 369
16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD. 370
16.21.1 COMPANY SNAPSHOT 370
16.21.2 PRODUCT PORTFOLIO 370
16.21.3 RECENT DEVELOPMENT 371
16.22 SK PLASMA 372
16.22.1 COMPANY SNAPSHOT 372
16.22.2 PRODUCT PORTFOLIO 372
16.22.3 RECENT DEVELOPMENT 373
16.23 SYNTHAVERSE S. A. 374
16.23.1 COMPANY SNAPSHOT 374
16.23.2 REVENUE ANALYSIS 375
16.23.3 PRODUCT PORTFOLIO 375
16.23.4 RECENT DEVELOPMENTS 376
16.24 TAIBANG BIO GROUP CO., LTD 377
16.24.1 COMPANY SNAPSHOT 377
16.24.2 PRODUCT PORTFOLIO 377
16.24.3 RECENT DEVELOPMENT 377
16.25 VIRCHOW BIOTECH 378
16.25.1 COMPANY SNAPSHOT 378
16.25.2 PRODUCT PORTFOLIO 378
16.25.3 RECENT DEVELOPMENT 380
17 QUESTIONNAIRE 381
18 RELATED REPORTS 384